BG — Bunge Global S.A.

Sell-side sentiment is strongly positive: 21 Buy ratings, 4 Hold, 0 Sell, with a consensus price target around $143. Q2 2026 adjusted EPS of $2.00 beat expectations, management raised full-year 2026 adjusted EPS guidance to $9.25-$9.75, and the stock has outperformed both the S&P 500 and the Consumer Staples sector over the trailing 12 months. The only tempering factor is that the stock has pulled back from its 52-week high and is not meaningfully oversold.

The trend is an inflection, not a clear multi-year organic trajectory, because Viterra closed around Q3 2025 and created a level shift: revenue went from $12.77B in Q2 2025 to $22.15B in Q3 2025 and has since run in a $21.9B-$24.0B quarterly range. GAAP EPS was weak through the back half of 2025 and Q1 2026 ($0.85, $0.49, $0.35), then jumped to $3.46 in Q2 2026. Operating margin improved from 0.4% in Q2 2025 and 0.6% in Q3 2025 to 4.5% in Q2 2026. That is a genuine margin recovery, but one quarter does not prove the new Viterra-based margin ceiling.

As of 2026-08-27, BG is optically rich on trailing earnings but reasonable on forward earnings. Trailing P/E is 21.7x versus a 5-year average of 10.0x, and P/S of 0.233x is just above the 5-year average of 0.22x. The trailing multiple is distorted by weak TTM GAAP EPS of $5.15. Using FY2026 consensus EPS of $9.517, the forward P/E is about 11.7x. That is above Bunge's historical average but not excessive if Viterra is delivering the margin recovery that Q2 2026 suggests.

The stock is pricing in a normal recovered year, not a blowout. At $111.57, the market is paying roughly 11.7x forward EPS, which leaves limited room for error but still values the earnings recovery less aggressively than the Street's $143 target implies. If BG only hits the low end of guidance at $9.25 and reverts to its 10x historical multiple, fair value is around $93; if it sustains $9.75 and earns a 13x multiple, fair value is around $127. The current price sits in the lower-middle of that range, so the reward depends on execution and multiple re-rating.

As of 2026-08-27, RSI stood at 47.08, which is neutral. Price was 0.31% above the 20-day SMA, 1.07% below the 50-day SMA, and 1.70% below the 200-day SMA. The stock is essentially range-bound around its moving averages rather than trending strongly. There is no clear technical entry signal; a decisive move above the 50-day would improve the setup, while a pullback toward recent support would offer a better risk/reward than chasing here.

• Geopolitical trade friction and shifting global ag flow patterns create volatility that Bunge's expanded Viterra infrastructure is positioned to arbitrage.
• Interest rates remain a swing factor: Bunge recently issued $600M of 5.000% notes due 2031, showing stable credit access but also higher carrying costs.
• Structurally solid demand for food, feed, and low-carbon renewable fuel feedstocks supports long-run volume growth.
• Rising El Nino probability adds weather-driven supply risk that could disrupt crop yields and crush margins into late 2026.
• Defensive sector rotation favors consumer staples, and BG's 0.65 beta and 2.48% dividend yield give it some ballast in a risk-off tape.

• Q3 2026 earnings on November 4, 2026, which will show late-season harvest volumes, South American planting, and continued Viterra integration.
• Barclays Global Consumer Conference on September 8, 2026, where management may give operational or strategic updates.
• Ongoing Viterra synergy realization and any further capital-return activity after completing the $2B repurchase program.
• Weather-driven crop disruptions or favorable crush-margin moves tied to El Nino uncertainty.

• Crush margins are cyclical and can mean-revert quickly; Q2 2026's margin strength may not persist.
• Viterra integration and higher leverage: long-term debt is $9.43B and debt-to-equity is 1.05x, leaving limited balance-sheet slack.
• Operating cash flow is sharply seasonal: Q1 and Q2 2026 free cash flow were -$877M and -$1.03B, respectively, making working capital and refinancing risk relevant.
• Geopolitical and trade-policy actions, including tariffs or export restrictions, can squeeze agribusiness margins despite creating trading volatility.

BG is a reasonable, cautious buy rather than a must-own. The Q2 beat and raised guidance show Viterra is beginning to add earnings power, and at roughly 11.7x forward EPS the market is not pricing in perfection. But this is a low-margin, commodity-cyclical business with lumpy cash flows and post-acquisition execution risk, so the upside will come from hitting guidance and sustaining margins, not from an automatic multiple re-rating.

Calculated by applying a 12.5x forward P/E to the FY2026 consensus EPS estimate of $9.517. That multiple is a modest premium to Bunge's five-year average P/E of 10.0x, reflecting Viterra scale, synergy potential, and the Q2 2026 margin recovery, but it is conservative versus the roughly 15x forward multiple implied by the consensus price target.